Rani Therapeutics (NASDAQ:RANI) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Rani Therapeutics (NASDAQ:RANI) announced its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04), FiscalAI reports. The company had revenue of $1.46 million during the quarter, compared to the consensus estimate of $5.00 million.

Here are the key takeaways from Rani Therapeutics’ conference call:

• Rani signed a collaboration and license with Chugai potentially worth up to $1.1 billion with an option for five additional targets, which management frames as validation of the RaniPill platform’s scalability and applicability across high‑value therapeutic areas.
• The company closed an oversubscribed $60.3 million private placement, received an upfront Chugai payment, ended 2025 with $49.7 million in cash and marketable securities, repaid all debt, and expects funding into the fourth quarter of 2027.
• RT‑114 (oral GLP‑1/GLP‑2) showed preclinical 111% relative bioavailability versus injected PG‑102 with comparable weight loss, and Rani initiated a Phase I‑B trial that includes weight‑loss PD endpoints—clinical replication would materially de‑risk the platform.
• Management implemented cost containment that reduced R&D and G&A spend and narrowed net loss year‑over‑year, but said R&D expenses are expected to rise as select programs resume.
• Accounting rules spread the Chugai upfront payment over time so only $1.5 million was recognized as 4Q25 revenue, and the company reported a FY2025 net loss of $41 million, underscoring continued reliance on future milestones and partnerships for material revenue.

Rani Therapeutics Price Performance

Shares of Rani Therapeutics stock opened at $0.81 on Friday. Rani Therapeutics has a 1 year low of $0.39 and a 1 year high of $3.87. The firm has a market cap of $98.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.39. The company has a 50-day moving average of $1.27 and a 200 day moving average of $1.30.

Analyst Ratings Changes

Several analysts recently weighed in on RANI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rani Therapeutics in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Rani Therapeutics in a research note on Friday. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.33.

Hedge Funds Weigh In On Rani Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in shares of Rani Therapeutics during the fourth quarter valued at approximately $69,000. Millennium Management LLC bought a new stake in shares of Rani Therapeutics in the 4th quarter worth approximately $220,000. Bridgeway Capital Management LLC purchased a new stake in shares of Rani Therapeutics in the 4th quarter worth approximately $155,000. 683 Capital Management LLC bought a new position in Rani Therapeutics during the 4th quarter valued at approximately $658,000. Finally, RA Capital Management L.P. purchased a new position in Rani Therapeutics during the fourth quarter valued at $11,475,000. Institutional investors own 30.19% of the company’s stock.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.